| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Division of Cardiology, University Hospital of Geneva (M.B., J.C., A.A., P.D.), CH-1211 Geneva, Switzerland; and Renal Division, Emory University (S.R.P., J.L.B., W.E.M.), Atlanta, Georgia 30322
Address all correspondence and requests for reprints to: Dr. Marijke Brink, Division of Cardiology, Fondation pour Recherches Médicales, 64 avenue de la Roseraie, CH-1211 Geneva, Switzerland. E-mail: marijke.brink{at}dim.hcuge.ch
We previously showed that angiotensin II (ang II) infusion in the rat produces cachexia and decreases circulating insulin-like growth factor I (IGF-I). The weight loss derives from an anorexigenic response and a catabolic effect of ang II. In these experiments we assessed potential catabolic mechanisms and the involvement of the IGF-I system in these responses to ang II. Ang II infusion caused a significant decrease in body weight compared with that of pair-fed control rats. Kidney and left ventricular weights were significantly increased by ang II, whereas fat tissue was unchanged. Skeletal muscle mass was significantly decreased in the ang II-infused rats, and a reduction in lean muscle mass was a major reason for their overall loss of body weight. In skeletal muscles, ang II did not significantly decrease protein synthesis, but overall protein breakdown was accelerated; inhibiting lysosomal and calcium-activated proteases did not reduce the ang II-induced increase in muscle proteolysis. Circulating IGF-I levels were 33% lower in ang II rats vs. control rats, and this difference was reflected in lower IGF-I messenger RNA levels in the liver. Moreover, IGF-I, IGF-binding protein-3, and IGF-binding protein-5 messenger RNAs in the gastrocnemius were significantly reduced. To investigate whether the reduced circulating IGF-I accounts for the loss in muscle mass, we increased circulating IGF-I by coinfusing ang II and IGF-I, but this did not prevent muscle loss. Our data suggest that ang II causes a loss in skeletal muscle mass by enhancing protein degradation probably via its inhibitory effect on the autocrine IGF-I system.
This article has been cited by other articles:
![]() |
A. P. Jayasooriya, M. L. Mathai, L. L. Walker, D. P. Begg, D. A. Denton, D. Cameron-Smith, G. F. Egan, M. J. McKinley, P. D. Rodger, A. J. Sinclair, et al. Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance PNAS, May 6, 2008; 105(18): 6531 - 6536. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Costelli, M. Muscaritoli, M. Bossola, F. Penna, P. Reffo, A. Bonetto, S. Busquets, G. Bonelli, F. J. Lopez-Soriano, G. B. Doglietto, et al. IGF-1 is downregulated in experimental cancer cachexia Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2006; 291(3): R674 - R683. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Paul, A. Poyan Mehr, and R. Kreutz Physiology of local Renin-Angiotensin systems. Physiol Rev, July 1, 2006; 86(3): 747 - 803. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. R. Adams and N. D. Vaziri Skeletal muscle dysfunction in chronic renal failure: effects of exercise Am J Physiol Renal Physiol, April 1, 2006; 290(4): F753 - F761. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. C. Schulze, J. Fang, K. A. Kassik, J. Gannon, M. Cupesi, C. MacGillivray, R. T. Lee, and N. Rosenthal Transgenic Overexpression of Locally Acting Insulin-Like Growth Factor-1 Inhibits Ubiquitin-Mediated Muscle Atrophy in Chronic Left-Ventricular Dysfunction Circ. Res., September 2, 2005; 97(5): 418 - 426. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Roelfsema, A. J. Gunn, B. H. Breier, J. S. Quaedackers, and L. Bennet The Effect of Mild Hypothermia on Insulin-like Growth Factors After Severe Asphyxia in the Preterm Fetal Sheep Reproductive Sciences, May 1, 2005; 12(4): 232 - 237. [Abstract] [PDF] |
||||
![]() |
A. Cabassi, P. Coghi, P. Govoni, E. Barouhiel, E. Speroni, S. Cavazzini, A. M. Cantoni, R. Scandroglio, and E. Fiaccadori Sympathetic Modulation by Carvedilol and Losartan Reduces Angiotensin II-Mediated Lipolysis in Subcutaneous and Visceral Fat J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2888 - 2897. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ishizaka, K. Saito, E. Noiri, M. Sata, H. Ikeda, A. Ohno, J. Ando, I. Mori, M. Ohno, and R. Nagai Administration of ANG II induces iron deposition and upregulation of TGF-{beta}1 mRNA in the rat liver Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2005; 288(4): R1063 - R1070. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Porter and K. R. Potratz Effect of intracerebroventricular angiotensin II on body weight and food intake in adult rats Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2004; 287(2): R422 - R428. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Rosen The Electrocardiogram 100 Years Later: Electrical Insights Into Molecular Messages Circulation, October 22, 2002; 106(17): 2173 - 2179. [Full Text] [PDF] |
||||
![]() |
N. Nagaya, M. Uematsu, M. Kojima, Y. Date, M. Nakazato, H. Okumura, H. Hosoda, W. Shimizu, M. Yamagishi, H. Oya, et al. Elevated Circulating Level of Ghrelin in Cachexia Associated With Chronic Heart Failure: Relationships Between Ghrelin and Anabolic/Catabolic Factors Circulation, October 23, 2001; 104(17): 2034 - 2038. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |